Skip to content

Prevention of overtraining syndrome in young (elite) athletes: Development of a monitor and advanced techniques for clinical diagnosis.

Prevention of overtraining syndrome in young (elite) athletes: Development of a monitor and advanced techniques for clinical diagnosis. - Prevention of overtraining syndrome

Status
Unknown
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON29839
Enrollment
150
Registered
2006-05-10
Start date
Unknown
Completion date
Unknown
Last updated
2024-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

overtraindheid bij sporters overreaching Staleness

Interventions

none.

Sponsors

Universitair Medisch Centrum Groningen
Lead Sponsor

Eligibility

Age
12 Years to 99 Years

Inclusion criteria

Inclusion criteria: Young elite athletes between 15 and 20 years, males.

Exclusion criteria

Exclusion criteria: Athletes suffering from any medical problem that is supposed to be a risk factor for maximal exercise testing or limits their exercise capacity (eg viral infections, anemia, allergy, medication, diabetes, hypothyreoidea, cardiac diseases) will not be included in the study sample.

Design outcomes

Primary

MeasureTime frame
Performance:Interval Shuttle Run Test (ISRT) for ball team players (22), Zoladz Test for runners and Cycle ergometer test for cyclists. Monitor: Recovery Stress Questionnaire for athletes (RESTQ-sport)

Secondary

MeasureTime frame
Changes in hormone profiles as a result of two graded max. exercise tests: ACTH, Prolactin, GH, and Cortisol. Finger Precuing Task (FPT) psychomotor speed. EEG:Power and coherence spectra (F3-P4, F4-P3, eyes-open and eyes-closed conditions 2 minutes each) for left/right balance and overall slowing (power), and for left-frontal/ right parietal coherence, measured before, during and after a stress test. Saliva cortisol is measured before and after the stress test.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)